Investor Presentations

Renalytix PLC

25 September 2026

 

Renalytix plc

(“Renalytix” or the “Company”)

Investor Presentations

LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next week and will be presenting at the MelloLondon2026 event in November. Details of the two events are below.

On-line presentation: Investor Meet Company

James McCullough, Chief Executive Officer, will provide a live presentation via Investor Meet Company at 16:00 BST on Tuesday, 29 September 2026. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation. 

Investors can sign up to Investor Meet Company for free and add to meet Renalytix Plc via:

https://www.investormeetcompany.com/renalytix-plc-1/register.

Investors who already follow Renalytix plc on the Investor Meet Company platform will automatically be invited.

In-person presentation: MelloLondon2026

Renalytix will also be presenting at the MelloLondon2026 investor event on Tuesday 17 November 2026. The event is taking place at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY. 

Renalytix will present twice during the event. There will also be opportunity to interact with the management team at the Company’s exhibitor stand. For further information and tickets for the MelloLondon2026 conference, please visit the event website at https://www.melloevents.com/mellolondon2026.

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker)		Tel: [phone]
David Hignell / Jen Clarke (Corporate Finance)
Vadim Alexandre (Corporate Broking)
Oberon Capital (Joint Broker)	Tel: [phone]
Mike Seabrook / Nick Lovering
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)

RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It’s KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.

Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States’ and the United Kingdom’s medical systems, affecting approximately 15 million and 8 million people, respectively.

RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.

 

END